Eu preciso de um metodo que receba como entrada um arquivo XML, e tenha como saída, um arquivo txt com o código fontee do arquivo xml
alguem pode me ajudar?
to olhando, mas acho que nao consigo mexer com Xstream, se alguem tiver uma outra solucao…agradeco
Amigo, não me entenda mal, mas se vc chegar e pedir “eu preciso de um sistema que faça isso”, dificilmente vc vai obter alguma resposta. A galera aqui ajuda, tira dúvidas, mas não faz aquilo que vc precisa pra vc. Coloque o seu código aqui que vamos te ajudando. Caso vc seja iniciante e não saiba como começar, tb deixe isso claro, p/ que possamos te ajudar de forma apropriada.
Blz? Flw! :thumbup:
pois eh, e isso que eu eu falei, eu nao tenho conhecimento suficiente para mexer com uma biblioteca extra como e o Xstream, eu to pedindo outras sugestoes, nao a resposta…
Bom, vc pode começar com estes tutoriais do guj:
:arrow: Manipulação de arquivos:
http://www.guj.com.br/java.tutorial.artigo.13.1.guj
:arrow: XStream: Trabalhando com facilmente XML em Java
http://www.guj.com.br/java.tutorial.artigo.144.1.guj
:arrow: Parseando XML com o DOM:
http://www.guj.com.br/java.tutorial.artigo.22.1.guj
:arrow: Parseando um XML com o SAX
http://www.guj.com.br/java.tutorial.artigo.15.1.guj
Use tb a busca do fórum, vc vai encontrar muito mais material sobre isso.
Blz? Flw! :thumbup:
valeu,…vou dar uma lida nele.s…
[quote=hcbelias]Eu preciso de um metodo que receba como entrada um arquivo XML, e tenha como saída, um arquivo txt com o código fontee do arquivo xml
[/quote]
O que seria o “codigo fonte” de um arquivo xml ?
O xml já é um texto. Abra um no notepad e verá.
o problema e que , se vc manda exibi o codigo fonte do xml, pelo browser, ele me da um tipo de codigo, se eu mando abri como arquivo texto, ele abre outro codigo diferente…
esse codigo que e aberto pelo browser, e o que eu preciso…
Eu utilizei o seguinte metodo para realizar esta operação
public static File emCodigoHtml(File arquivo) throws IOException {
File arquivohtml = new File("arquivos",arquivo.getName());
FileReader leitor = new FileReader(arquivohtml);
char[] conteudo = new char[ (int) arquivohtml.length() ];
leitor.read( conteudo );
leitor.close();
String texto = new String( conteudo );
File arquivotxt=new File(".","entradatxt.txt");
FileWriter gravador=new FileWriter(arquivotxt);
PrintWriter imprime=new PrintWriter(gravador);
imprime.print(texto);
imprime.close();
return arquivotxt;
}
o codigo que eu esperaria que retornasse seria ::
DailyMed: About DailyMed<li><a class="skipicon1" href="#druglabelcontent" title="Skip to DrugLabel content paragraph">Skip to DrugLabel content</a></li>
<li><a class="skipicon2" href="#dmsections" title="Skip to DrugLabel sections paragraph">Skip to DrugLabel sections</a></li>
Daily Med
Current Medication Information
Options
- Home
- E-mail Label Information
-
Downloads
- Download All Drug Labels
<li> <a title=" Link opens new window to download this label (XML) " href="/dailymed/getFile.cfm?id=4687&type=zip&name=A-HYDROCORT">Download this Label(XML)</a> </li> <li> <a href="http://www.fda.gov/oc/datacouncil/spl.html" title="Link opens in a new window for FDA SPL Resources" target="FDA">FDA SPL XML Schema</a> </li> </ul> </li> <li><a title="Link to Print this Label" href="/dailymed/fda/fdaDrugXsl.cfm?id=4687&type=display" id="printitem" target="_blank"> Print this Label </a> </li> <li> <a title=" Notify of Updates " href="/dailymed/rsshome.cfm" id="rss">Notify of Updates</a> </li> <li> <a title=" Contact Us " href="/dailymed/contactUs.cfm" id="contact">Contact Us</a> </li> <li><h2>Additional Resources</h2></li> <li> <a id="report" href="http://www.fda.gov/medwatch/how.htm" target="FDA" title="FDA Page to Report Adverse Event">Report Adverse Event</a> </li> <li><a href="http://search.nlm.nih.gov/medlineplusDrugs/query?DISAMBIGUATION=true&FUNCTION=search&SERVER2=server2&SERVER1=server1&PARAMETER=Hydrocortisone" title="Link opens new window to MedlinePlus Information" target="medlinePlus">MedlinePlus Information</a></li> <li><a href="http://www.clinicaltrials.gov/ct/search?submit=Search&term=Hydrocortisone" title="Link opens new window to Find Clinical Trials" target="clinicalTrials">Find Clinical Trials</a></li> <li><a href="http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=APRD01019" title="Link opens new window to University of Alberta DrugBank " target="drugBank">Biochemical Data Summary</a></li> <li><a href="#" class="rightarrow" title="Links to Search PubMed Articles">Search PubMed Articles</a> <ul> <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed&term=Hydrocortisone[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a></li> <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed&term=Hydrocortisone/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a></li> <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed&term=Hydrocortisone/TU" title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a></li> <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed&term=Hydrocortisone/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a></li> <li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed&term=Hydrocortisone[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a></li> </ul> </li> <li> <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+lact:@na+Hydrocortisone" target="toxnet" title="Link opens new window for Presence in Breast Milk">Presence in Breast Milk</a> </li> </ul> <div id="mdswitch"> <a href="/dailymed/drugInfo.cfm?id=4687&dictionary=on" title="Turn Dictionary Words On"> <img src="/dailymed/images/dictionaryon.jpg" alt="Turn Dictionary Words On"/> </a> </div> </div>
For a FDA View of this Label, click here
Search By Drug Name:
<div id="rxnormlist">
<h3>RxNorm Names</h3>
<ul style="maring:0px; padding:0px;">
<li id="item1" style="padding:1px; margin:1px;">
<a id="viewrxnorm"
href="rxnormdata.cfm?id=4687"
onclick="rxnormpopup(this.href);return false;"
target="rxnorm" title="Link to Review RxNorm Normal Forms" >
<img src="images/closed.gif"
alt="Icon attached Review or Hide All RxNorm Normal Forms Link"
id="img_item1"
border="0"
style="clear:none;float:left">Review RxNorm Normal Forms</a>
</li>
</ul>
</div>
a-hydrocort (Hydrocortisone Sodium Succinate) injection, powder, lyophilized, for solution
[Hospira, Inc.]
Drug Label Sections
Hydrocortisone Sodium Succinate
for Injection, USP
Rx only
For Intravenous or Intramuscular Administration
DESCRIPTION
A-Hydrocort sterile powder contains hydrocortisone sodium succinate as the active ingredient. Hydrocortisone sodium succinate, is a white, or nearly white, odorless, hygroscopic, amorphous solid. It is very soluble in water and in alcohol, very slightly soluble in acetone and insoluble in chloroform. The chemical name is pregn-4-ene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11β)- and its molecular weight is 484.52.
The structural formula is represented below:
Hydrocortisone sodium succinate is an anti-inflammatory adrenocortical steroid. This highly water-soluble sodium succinate ester of hydrocortisone permits the immediate intravenous administration of high doses of hydrocortisone in a small volume of diluent and is particularly useful where high blood levels of hydrocortisone are required rapidly.
A-Hydrocort sterile powder is available for intravenous or intramuscular administration.
100 mg− Vials containing hydrocortisone sodium succinate equivalent to 100 mg hydrocortisone, also 0.8 mg monobasic sodium phosphate anhydrous, 8.73 mg dibasic sodium phosphate anhydrous.
When necessary, the pH was adjusted with sodium hydroxide so that the pH of the reconstituted solution is within the USP specified range of 7 to 8.
For intravenous or intramuscular injection, vial should be reconstituted with Bacteriostatic Water for Injection or Bacteriostatic Sodium Chloride.
For intravenous infusion, vial should be reconstituted with Bacteriostatic Water for Injection.
CLINICAL PHARMACOLOGY
Hydrocortisone sodium succinate has the same metabolic
and anti-inflammatory actions as hydrocortisone. When given parenterally
and in equimolar quantities, the two compounds are equivalent in biologic
activity. Following the intravenous injection of hydrocortisone sodium
succinate, demonstrable effects are evident within one hour and persist
for a variable period. Excretion of the administered dose is nearly
complete within 12 hours. Thus, if constantly high blood levels are
required, injections should be made every 4 to 6 hours. This preparation
is also rapidly absorbed when administered intramuscularly and is
excreted in a pattern similar to that observed after intravenous injection.
INDICATIONS AND USAGE
When oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, A-Hydrocort sterile powder is indicated for intravenous or intramuscular use in the following conditions:
Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance)
Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used)
Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful
Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected
Congenital adrenal hyperplasia
Hypercalcemia associated with cancer
Nonsuppurative thyroiditis
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Post-traumatic osteoarthritis
Synovitis of osteoarthritis
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Acute and subacute bursitis
Epicondylitis
Acute nonspecific tenosynovitis
Acute gouty arthritis
Psoriatic arthritis
Ankylosing spondylitis
Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
Dermatologic Diseases
Pemphigus
Severe erythema multiforme (Stevens-Johnson syndrome)
Exfoliative dermatitis
Bullous dermatitis herpetiformis
Severe seborrheic dermatitis
Severe psoriasis
Mycosis fungoides
Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:
Bronchial asthma
Contact dermatitis
Atopic dermatitis
Serum sickness
Seasonal or perennial allergic rhinitis
Drug hypersensitivity reactions
Urticarial transfusion reactions
Acute noninfectious laryngeal edema (epinephrine is the drug of first choice)
Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye, such as:
Herpes zoster ophthalmicus
Iritis, iridocyclitis
Chorioretinitis
Diffuse posterior uveitis and choroiditis
Optic neuritis
Sympathetic ophthalmia
Anterior segment inflammation
Allergic conjunctivitis
Allergic corneal marginal ulcers
Keratitis
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis (systemic therapy)
Regional enteritis (systemic therapy)
Respiratory Diseases
Symptomatic sarcoidosis
Berylliosis
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Loeffler’s syndrome not manageable by other means
Aspiration pneumonitis
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia
Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated)
Secondary thrombocytopenia in adults
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
Edematous States
To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus
Nervous System
Acute exacerbations of multiple sclerosis
Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
Trichinosis with neurologic or myocardial involvement
CONTRAINDICATIONS
The use of A-Hydrocort sterile powder is contraindicated in premature infants because the 100 mg vial is reconstituted with Bacteriostatic Water for Injection or Bacteriostatic Sodium Chloride Injection containing benzyl alcohol. Benzyl alcohol has been reported to be associated with a fatal “Gasping Syndrome” in premature infants. A-Hydrocort sterile powder is also contraindicated in systemic fungal infections and patients with known hypersensitivity to the product and its constituents.
WARNINGS
In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.
Corticosteroids may mask some signs of infection, and new infections may appear during their use. There may be decreased resistance and inability to localize infection when corticosteroids are used.
Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.
Usage in pregnancy. Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers, or women of childbearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.
Average and large doses of hydrocortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.
While on corticosteroid therapy patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response.
The use of A-Hydrocort sterile powder in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with appropriate antituberculous regimen.
If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.
Because rare instances of anaphylactoid reactions (eg, bronchospasm) have occurred in patients receiving parenteral corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of allergy to any drug.
Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered.
PRECAUTIONS
General Precautions
Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.
There is an enhanced effect of corticosteroids in patients with hypothyroidism and in those with cirrhosis.
Corticosteroids should be used cautiously in patients with ocular herpes simplex for fear of corneal perforation.
The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction must be gradual.
Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.
Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection, also in diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, renal insufficiency, hypertension, osteoporosis, and myasthenia gravis.
Growth and development of infants and children on prolonged corticosteroid therapy should be carefully followed.
Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See DOSAGE AND ADMINISTRATION).
Since complications of treatment with glucocorticoids are dependent on the size of the dose and duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.
DRUG INTERACTIONS
The pharmacokinetic interactions listed below are potentially clinically important. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity. Corticosteroids may increase the clearance of chronic high-dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. The effect of corticosteroids on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.
Information for the Patient
Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.
ADVERSE REACTIONS
Fluid and Electrolyte Disturbances
Sodium retention, Fluid retention, Congestive heart failure in susceptible patients, Potassium loss, Hypokalemic alkalosis, Hypertension
Musculoskeletal
Muscle weakness, Steroid myopathy, Loss of muscle mass, Osteoporosis, Vertebral compression fractures, Aseptic necrosis of femoral and humeral heads, Pathologic fracture of long bones
Gastrointestinal
Peptic ulcer with possible perforation and hemorrhage, Pancreatitis, Abdominal distention, Ulcerative esophagitis
Dermatologic
Impaired wound healing, Thin fragile skin, Petechiae and ecchymoses, Facial erythema, Increased sweating, May suppress reactions to skin tests
Neurological
Convulsions, Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment, Vertigo, Headache
Endocrine
Menstrual irregularities, Development of Cushingoid state, Suppression of growth in children, Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness, Decreased carbohydrate tolerance, Manifestations of latent diabetes mellitus, Increased requirements of insulin or oral hypoglycemic agents in diabetics
Ophthalmic
Posterior subcapsular cataracts, Increased intraocular pressure, Glaucoma, Exophthalmos
Metabolic
Negative nitrogen balance due to protein catabolism
The following additional reactions are related to parenteral corticosteroid therapy:
Allergic, anaphylactic or other hypersensitivity reactions, Hyperpigmentation or hypopigmentation, Subcutaneous and cutaneous atrophy, Sterile abscess
DOSAGE AND ADMINISTRATION
This preparation may be administered by intravenous injection, by intravenous infusion, or by intramuscular injection, the preferred method for initial emergency use being intravenous injection. Following the initial emergency period, consideration should be given to employing a longer acting injectable preparation or an oral preparation.
Therapy is initiated by administering A-Hydrocort sterile powder intravenously over a period of 30 seconds (eg, 100 mg) to 10 minutes (eg, 500 mg or more). In general, high-dose corticosteroid therapy should be continued only until the patient’s condition has stabilized − usually not beyond 48 to 72 hours. Although adverse effects associated with high-dose, short-term corticoid therapy are uncommon, peptic ulceration may occur. Prophylactic antacid therapy may be indicated.
When high-dose hydrocortisone therapy must be continued beyond 48-72 hours, hypernatremia may occur. Under such circumstances it may be desirable to replace hydrocortisone sodium succinate with a corticoid such as methylprednisolone sodium succinate which causes little or no sodium retention.
The initial dose of A-Hydrocort sterile powder is 100 mg to 500 mg, depending on the severity of the condition. This dose may be repeated at intervals of 2, 4 or 6 hours as indicated by the patient’s response and clinical condition. While the dose may be reduced for infants and children, it is governed more by the severity of the condition and response of the patient than by age or body weight but should not be less than 25 mg daily.
Patients subjected to severe stress following corticosteroid therapy should be observed closely for signs and symptoms of adrenocortical insufficiency.
Corticoid therapy is an adjunct to, and not a replacement for, conventional therapy.
Preparation of Solutions
100 mg − For intravenous or intramuscular injection, prepare solution by aseptically adding not more than 2 mL of Bacteriostatic Water for Injection or Bacteriostatic Sodium Chloride Injection to the contents of one vial. Further dilution is not necessary for intravenous or intramuscular injection. For intravenous infusion, first prepare solution by adding not more than 2 mL of Bacteriostatic Water for Injection to the vial; this solution may then be added to 100 to 1000 mL of the following: 5% dextrose in water (or isotonic saline solution or 5% dextrose in isotonic saline solution if patient is not on sodium restriction). In cases where administration of a small volume of fluid is desirable, 100 mg of hydrocortisone sodium succinate may be added to 50 mL of the above diluents. The resulting solutions are stable for at least 4 hours and may be administered either directly or by IV piggyback.
When reconstituted as directed, pH’s of the solutions range from 7 to 8 and the tonicities are: 100 mg vial, .36 osmolar. (Isotonic saline = .28 osmolar.)
HOW SUPPLIED
A-Hydrocort sterile powder is available in the following package:
|
List |
Container |
Concentration |
|
4856 |
Single-Dose Vial |
100 mg |
STORAGE CONDITIONS
Store unreconstituted product at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]
Store solution at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from light.
Use solution only if it is clear. Unused solution should be discarded after 3 days.
Lyophilized in container.
Revised: October, 2005
| ©Hospira 2005 | EN-1070 | Printed in USA |
| HOSPIRA, INC., LAKE FOREST, IL 60045 USA |
| A-HYDROCORT (Hydrocortisone Sodium Succinate) | |||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
|
Revised: 07/2007Hospira, Inc.
Copyright,
Privacy,
AccessibilityU.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services
Loprox(ciclopirox 1%) Shampoo
MEDICIS Pharmaceutical Corp.
LOPROX
ciclopirox
ciclopirox
ciclopirox
Water
Sodium Laureth Sulfate
Disodium Laureth Sulfosuccinate
Sodium Chloride
Laureth-2
Rx Only
FOR TOPICAL USE ONLY
NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE
KEEP OUT OF REACH OF CHILDREN
DESCRIPTION
LOPROX® (ciclopirox) Shampoo 1% contains the synthetic antifungal agent, ciclopirox.Each gram (equivalent to 0.96 mL) of LOPROX Shampoo contains 10 mg ciclopirox in a shampoo base consisting of Purified Water USP, Sodium Laureth Sulfate, Disodium Laureth Sulfosuccinate, Sodium Chloride USP, and Laureth-2.LOPROX Shampoo is a colorless, translucent solution. The chemical name for ciclopirox is 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, with the empirical formula C12H17NO2 and a molecular weight of 207.27. The CAS Registry Number is [29342-05-0]. The chemical structure is:
CLINICAL PHARMACOLOGY
Mechanism of Action
Ciclopirox is a hydroxypyridone antifungal agent although the relevance of this property for the indication of seborrheic dermatitis is not known. Ciclopirox acts by chelation of polyvalent cations (Fe3+ or Al3+), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.
Pharmacokinetics and Pharmacodynamics
In a study in patients with seborrheic dermatitis of the scalp, application of 5 mL ciclopirox shampoo 1% twice weekly for 4 weeks, with an exposure time of 3 minutes per application, resulted in detectable serum concentrations of ciclopirox in 6 out of 18 patients. The serum concentrations measured throughout the dosing interval on Days 1 and 29 ranged from 10.3 ng/mL to 13.2 ng/mL. Total urinary excretion of ciclopirox was less than 0.5% of the administered dose.
CLINICAL STUDIES
In two randomized, double-blind clinical trials, patients 16 years and older with seborrheic dermatitis of the scalp applied LOPROX Shampoo or its vehicle two times per week for 4 weeks. Patients who were immunocompromised, those with psoriasis or atopic dermatitis, women of childbearing potential not using adequate contraception, and pregnant or lactating women were excluded from the clinical studies. An evaluation of the overall status of the seborrheic dermatitis, and the presence and severity of erythema or inflammation, and scaling, was made at week 4, using a scale of 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = pronounced, and 5 = severe. Effective treatment was defined as achieving a score of 0 (or a score of 1 if the baseline score was ≥ 3) simultaneously for status of the seborrheic dermatitis, erythema or inflammation, and scaling at Week 4. Ciclopirox shampoo was shown to be statistically significantly more effective than vehicle in both studies. Efficacy results for the two studies are presented in the following table.Effective Treatment Rates at Week 4 in Studies 1 and 2
Ciclopirox Shampoo
Vehicle
Study 1
220/380 (58%)
60/192 (31%)
Study 2
65/250 (26%)
32/249 (13%)
Efficacy for black patients was not demonstrated, although only 53 black patients were enrolled in the two pivotal studies.
Microbiology
Ciclopirox is fungicidal in vitro against Malassezia furfur (Pityrosporum spp.), P. ovale, and P. orbiculare. Ciclopirox acts by chelation of polyvalent cations (Fe3+ or Al3+), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.The clinical significance of antifungal activity in the treatment of seborrheic dermatitis is not known.
INDICATIONS AND USAGE
LOPROX Shampoo is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults.
CONTRAINDICATIONS
LOPROX Shampoo is contraindicated in individuals who have shown hypersensitivity to any of its components.
WARNINGS
LOPROX Shampoo is not for ophthalmic, oral, or intravaginal use.Keep out of reach of children.
PRECAUTIONS
General
If a reaction suggesting sensitivity or irritation should occur with the use of LOPROX Shampoo, treatment should be discontinued and appropriate therapy instituted.Contact of LOPROX Shampoo with the eyes should be avoided. If contact occurs, rinse thoroughly with water.Seborrheic dermatitis may appear at puberty, however, no clinical studies have been done in patients younger than 16 years.In patients with lighter hair color, hair discoloration has been rarely reported.There is no relevant clinical experience with patients who have a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, recent or recurring herpes zoster, or persistent herpes simplex), who are immunocompromised (e.g., HIV-infected patients and transplant patients), or who have a diabetic neuropathy.
Information for Patients
The patient should be instructed to:Use LOPROX Shampoo as directed by the physician. Avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water. LOPROX Shampoo is for external use on the scalp only. Do not swallow.Use the medication for seborrheic dermatitis for the full treatment time even though symptoms may have improved. Notify the physician if there is no improvement after 4 weeks.Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, or oozing) indicative of possible allergic reaction.Not use the medication for any disorder other than that for which it is prescribed.
Carcinogenesis, Mutagenesis, and Impairment of Fertility
Long-term animal studies have not been performed to evaluate the carcinogenic potential of LOPROX Shampoo or ciclopirox.The following in vitro genotoxicity tests have been conducted with ciclopirox: evaluation of gene mutation in the Ames Salmonella and E. coli assays (negative); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells, with and without metabolic activation (positive); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells in the presence of supplemental Fe3+, with and without metabolic activation (negative); gene mutation assays in the HGPRT-test with V79 Chinese hamster lung fibroblast cells (negative); and a primary DNA damage assay (i.e., unscheduled DNA synthesis assay in A549 human cells) (negative). An in vitro cell transformation assay in BALB/c 3T3 cells was negative for cell transformation. In an in vivo Chinese hamster bone marrow cytogenetic assay, ciclopirox was negative for chromosome aberrations at a dosage of 5000 mg/kg body weight.A combined oral fertility and embryofetal developmental study was conducted in rats with ciclopirox olamine. No effect on fertility or reproductive performance was noted at the highest dose tested of 3.85 mg/kg/day ciclopirox (approximately 1.3 times the maximum recommended human dose based on body surface area comparisons).
Pregnancy
Teratogenic effects: Pregnancy Category B
Oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. Ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively).Dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in PEG 400. Ciclopirox olamine was topically administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 31 and 54 times the maximum recommended human dose based on body surface area comparisons, respectively).There are no adequate or well-controlled studies of topically applied ciclopirox in pregnant women. Because animal reproduction studies are not always predictive of human response, LOPROX Shampoo should be used during pregnancy only if clearly needed.
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when LOPROX Shampoo is administered to a nursing woman.
Pediatric Use
Seborrheic dermatitis may appear at puberty, however, no clinical studies have been done in patients younger than 16 years.
Geriatric Use
In clinical studies, the safety and tolerability of LOPROX Shampoo in the population 65 years and older was comparable to that of younger subjects. Results of the efficacy analysis in those patients 65 years and older showed effectiveness in 25 of 85 (29%) patients treated with LOPROX Shampoo, and in 15 of 61 (25%) patients treated with the vehicle; due to the small sample size, a statistically significant difference was not demonstrated. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity to adverse effects in some older individuals cannot be ruled out.
ADVERSE REACTIONS
In 626 patients treated with LOPROX Shampoo twice weekly in the two pivotal clinical studies, the most frequent adverse events were increased itching in 1% of patients, and application site reactions, such as burning, erythema, and itching, also in 1% of patients. Other adverse events occurred in individual patients only.Adverse events that led to early study medication termination in clinical trials occurred in 1.5% (26/1738) of patients treated with LOPROX Shampoo and 2.0% (12/661) of patients treated with shampoo vehicle. The most common adverse events leading to termination of study medication in either group was seborrhea. In the LOPROX Shampoo group, other adverse events included rash, pruritus, headache, ventricular tachycardia, and skin disorder. In the shampoo vehicle group, other adverse events included skin disorder and rash.
DOSAGE AND ADMINISTRATION
Wet hair and apply approximately 1 teaspoon (5 mL) of LOPROX Shampoo to the scalp. Up to 2 teaspoons (10 mL) may be used for long hair. Lather and leave on hair and scalp for 3 minutes. A timer may be used. Avoid contact with eyes. Rinse off. Treatment should be repeated twice per week for 4 weeks, with a minimum of 3 days between applications.If a patient with seborrheic dermatitis shows no clinical improvement after 4 weeks of treatment with LOPROX Shampoo, the diagnosis should be reviewed.
HOW SUPPLIED
LOPROX ® (ciclopirox) Shampoo 1% is supplied in 120 mL plastic bottles (NDC 99207-010-10). Discard unused product after initial treatment duration. Store between 15°C and 30°C (59°F and 86°F).
Manufactured for:
MEDICIS® Pharmaceutical Corp.
Scottsdale, AZ 85258PRESCRIBING INFORMATION AS OF JUNE 2006IN-5322/S
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------
alguem pode me ajudar?
Cara, pelo amor de Deus, use a tag code!
Você tem um html ou xml na tua máquina e quer gravar em um arquivo texto, é isso? Tente explicar melhor…
eu tenho um arquivo xml, e preciso d codigo xml, entretanto o codigo que o metodo retorna nao e xml…
entendeu?
Cara, como assim código xml? Se você tem um arquivo xml, acabou, não existe código xml!
E de que método você está falando? E se não retorna xml, retorna o que?
O xml contém a seguinte instrução
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?>Isto significa que o xml será transformado por aquela folha de estilo (spl.xsl).
Isto significa que o browser irá mostar o xhtml que resulta da transformação e não o xml.
O que está escrito no arquivo é o xml. O codigo que vc espera obter ( o xhtml) não está escrito em nenhum arquivo. Ele é gerado dinamicamente pelo browser ao associar a folha de estilo no xml.
Enfim, se o que lhe interessa é o codigo xml, vc já o tem. É o que están o arquivo.
Se o que lhe interessa é o codigo html, vc terá que o gerar.